Cellectar granted u.s. fda breakthrough therapy designation for iopofosine i 131 in waldenstrom macroglobulinemia (wm)

Designation supported by clover wam phase 2 study data which reported an 83.6% overall response rate (orr) seeking guidance from ema to determine if clover wam phase 2 data meets criteria to apply for fast-track, conditional marketing authorization, answer expected late july florham park, n.j., june 04, 2025 (globe newswire) -- cellectar biosciences, inc. (nasdaq: clrb), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the u.s. food and drug administration (fda) has granted breakthrough therapy designation for iopofosine i 131, a potential first-in-class, novel cancer targeting agent utilizing a phospholipid ether as a radioconjugate monotherapy, for the treatment of relapsed/refractory waldenstrom macroglobulinemia (r/r wm).
CLRB Ratings Summary
CLRB Quant Ranking